Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Milrinone Articles

China Sky One Medical’s Tianlong subsidiary to focus R&D efforts on antibiotics and cardiac drugs

22 January 2010

FDA clears Bioniche's Primacor generic

21 July 2003

Sanofi-Synthelabo forecasting steady growth, denies rumors of a merger

24 February 2003

Sanofi-Synthelabo sales climb 15.4%, driven by three blockbusters

29 April 2002

Three blockbusters continue to drive Sanofi-Synthelabo sales growth

28 January 2002

Sanofi-Synthelabo sales push $1.3 billion

26 April 2000

Sanofi-Synthelabo's three blockbusters push 1999 sales to 5.35 billion euros

27 January 2000

Sanofi-Synthelabo sales up 9% in 3rd quarter

1 November 1999

Sanofi-Synthelabo 1st-half profits up 18%

1 September 1999

New drugs boost Sanofi's 1998 sales

27 January 1999

New drugs boost Sanofi's 1998 sales

25 January 1999

Sanofi First-Half Profits Climb 12%

2 September 1998

Sanofi Produces Strong First-Half Sales Growth

24 July 1998

Sanofi Pharma Sales Held Back In West Europe, But Up 10%

4 February 1998

SANOFI LAUNCH

2 November 1992

BOEH INGELHEIM CHF DRUG DISCONTINUED

23 March 1992

Showing 1-16 of 16 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • New Zealand declines Alexion's funding application for Solaris
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • New Zealand declines Alexion's funding application for Solaris
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS